ArticleDisease models & mechanisms2026
Identification and credentialing of patient-derived xenograft models of invasive lobular carcinoma.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
Invasive lobular cancer (ILC) is the most common special breast cancer subtype, accounting for 10-15% of all cases. The pathognomonic feature of ILC is loss of E-cadherin (encoded by CDH1), leading to discohesive single-file growth. Although ILCs show better prognostic factors than 'no special type' (NST) breast cancer, patients with ILC have worse long-term outcomes. We identified and validated patient-derived xenograft (PDX) models of ILC from 122 breast cancer PDX models based on truncating CDH1 mutations and/or low CDH1 mRNA expression. Eight PDX models were selected for validation using immunohistochemistry for E-cadherin, p120, estrogen receptor, progesterone receptor and HER2. Seven models were confirmed as ILC, and one showed mixed NST-ILC features. Confirmed ILC PDX models showed enrichment of truncating CDH1 mutations, significantly lower CDH1 mRNA expression and predominantly luminal subtypes compared to NST models, consistent with human ILC characteristics. Commonly altered genes included PIK3CA (57%), CDH1 (57%) and TP53 (57%). These validated ILC PDX models provide valuable tools to advance understanding of ILC biology and support development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.